BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » mesenchymal stem cells » Page 4

Cynata Announces Japanese Patent Office to Grant Patent for Cymerus™ MSC Technology

May 3, 2016 By Cade Hildreth (CEO) 1 Comment

Cynata Announces Japanese Patent Office Decision to Grant Patent for Cymerus™ MSC technology

Cynata TherapeuticsCynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange  (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.

To learn more, read the full press release from Cynata Therapeutics, included below with permission Dr. Ross Macdonald, CEO of Cynata Therapeutics.


Cynata Announces Japanese Patent Office Decision to Grant Patent for Cymerus™ MSC Technology

Melbourne, Australia; 2 May 2016 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced that the Japanese Patent and Trademark Office has issued a Decision to Grant a patent covering certain aspects of its proprietary Cymerus™ mesenchymal stem cell (MSC) manufacturing technology. [Read more…]

Filed Under: iPS Cells, MSCs, Stem Cells Tagged With: Cymerus, cynata therapeutics, mesenchymal stem cells, patent

What Does Google Reveal about Mesenchymal Stem Cell (MSC) Trends?

April 26, 2016 By Cade Hildreth (CEO) Leave a Comment

What Does Google Trends Reveal about Mesenchymal Stem Cell (MSC) Trends

Google Trends is a supplemental service of Google Incorporated that analyzes trend data collected through Google Search.

Importantly, it shows how often a particular search term is entered relative to total search-volume across various regions of the world and in various languages.

It is an absolutely incredible market research tool for assessing stem cell market dynamics, because it reflects real-time social behavior related to specific stem cell types and provides public access to Google’s online search information. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: data trends, Google, Google Trends, mesenchymal stem cells

Pluristem Enters into Licensing Agreement with TES Holdings to Acquire Rights for Placental Cell Therapy Patent

April 21, 2016 By Cade Hildreth (CEO) Leave a Comment

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke - Depositphotos_42786767_m-2015.jpg

Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.  Pluristem’s core technology is placenta-derived cells that are being developed as a real ‘off-the-shelf’ therapeutic product for critical high unmet need indications, where there are limited or no alternative treatment options available. For example, Pluristem’s lead product, PLX PAD is in clinical development for diseases such as critical limb ischemia (CLI) and hip fractures.

In major news released today, Pluristem announced that it entered into a licensing agreement with TES Holdings Co., Ltd. to obtain a key patent in Japan that will cover the treatment of ischemic diseases with placental cell therapy. This is a significant announcement, as the company released news last week that it had been granted two key cell therapy patents in Japan.

To learn more, see the full press release issued by Pluristem below or read our recent interview with Dr. Racheli Ofir, VP Research & Intellectual Property at Pluristem Therapeutics.


Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

Press Release; Haifa, Israel, April 21, 2016 — Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PLTR), a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company’s IP coverage. This license follows Pluristem’s recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: cell therapy, ischemic diseases, mesenchymal stem cells, patent, Pluristem Therapeutics, TES Holdings

Criteria and Characteristics for Identifying Mesenchymal Stem Cells (MSC)

April 16, 2016 By Cade Hildreth (CEO) Leave a Comment

Criteria and Characteristics for Identifying Mesenchymal Stem Cells (MSC)

The criteria used to identify mesenchymal stem cells can vary, as identification s can be accomplished through assessing either physical or functional attributes.

Physical Assessment of Mesenchymal Stem Cells (MSCs)

The first approach is physical assessment. Morphologically, MSCs have a small cell body with long, thin cell processes that can give the cells a “stretched” appearance.  The cell body contains a large, round nucleus with a prominent nucleolus.  The cells present with symmetrical morphology.

MSCs tend to be broadly dispersed within an extracellular matrix (ECM) that contains a few reticular fibrils but lacks other types of collagen fibrils.

Functional Attributes of Mesenchymal Stem Cells (MSCs)

A second approach for identifying mesenchymal stem cells is through functional assessment.  Criteria for identifying MSCs are presented below:

  • Able to be isolated by plastic adherence
  • Have multi-potential and multi-lineage capability (plasticity)
  • Distinctive Surface Markers, specifically: CD73, CD90, CD105[1]
  • Lack of Lineage-Specific Markers, including: CD34, CD14, CD45[2]
  • Immuno-favorable characteristics that include little to no expression of MHC class I antigens and very limited expression of MHC class II antigens[3]
  • Lack of co-stimulatory molecules of the B7 family that are required to initiate an immune response

In addition, functional assessment can include analyzing cells for characteristic cytokine production or gene expression profiles.  However, the difficulty with this approach is that the “characteristic” cytokines produced or genes expressed by MSCs can vary by source of origin. For instance, bone marrow-derived MSCs and adipose-derived MSCs exhibit different, source-specific, cytokine production.[4]

FOOTNOTES:

[1] Klingemann H, et al. Mesenchymal Stem Cells, Sources and Applications. Transfusion Medicine and Hemotherapy 2008; 35: 272-277
[2] Friedman R, Betancur M, Tuncer H, Boissel L, Klingemann H. Umbilical cord mesenchymal stem cells: Adjuvants for human cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1477–1486.
[3] Friedman R, Betancur M, Tuncer H, Boissel L, Klingemann H. Umbilical cord mesenchymal stem cells: Adjuvants for human cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1477–1486.
[4] Gonzalez-Rey E, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 241-248.

 

Filed Under: MSCs Tagged With: criteria, mesenchymal stem cells

4 Key Areas for Basic Research on Mesenchymal Stem Cells (MSCs)

April 16, 2016 By Cade Hildreth (CEO) Leave a Comment

4 Key Areas for Basic Research on Mesenchymal Stem Cells (MSCs)

To advance scientific progress with any cell type, a basic level of knowledge needs to be acquired, including protocols for cell isolation, growth, expansion, differentiation, and more. It requires that characteristics of the cells be observed to determine how they are affected by environmental variation. To date, a significant amount has been learned about mesenchymal stem cells, as 30,697 scientific articles have been published about the cell type.[1]  Of those, more than half (17,998) have been published within the last five years.[2] [Read more…]

Filed Under: MSCs Tagged With: mesenchymal stem cells, stem cell differentiation

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 12
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.